CRISPR Therapeutics AG(NASDAQ : CRSP)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.49%||64.15||1.0%||$544.64m|
|VRTX||Vertex Pharmaceuticals, Inc.||4.32%||269.76||1.9%||$481.90m|
|REGN||Regeneron Pharmaceuticals, Inc.||3.67%||685.42||2.6%||$437.60m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-0.47%||2.10||0.7%||$146.80m|
|EXAS||EXACT Sciences Corp.||-2.13%||52.04||17.7%||$143.96m|
|BMRN||BioMarin Pharmaceutical, Inc.||1.29%||80.75||4.2%||$99.68m|
|TXG||10X Genomics, Inc.||-1.75%||49.28||0.0%||$99.51m|
CRISPR Therapeutics AG is a gene editing company, which is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.